Icon ( (ICLR) ) has shared an announcement.
On March 12, 2025, ICON plc released its unaudited non-consolidated non-statutory interim financial statements for the period from January 1, 2024, to March 5, 2025. The report highlighted a significant profit before taxation of $676,070,000, primarily driven by income from shares in group undertakings. Despite an operating loss of $8,546,000, the substantial income from shares indicates a strong financial position, potentially enhancing ICON’s market standing and stakeholder confidence.
More about Icon
ICON plc operates in the healthcare and pharmaceutical industry, providing clinical research and development services. The company is headquartered in Dublin, Ireland, and focuses on delivering comprehensive solutions to pharmaceutical, biotechnology, and medical device industries.
YTD Price Performance: -17.33%
Average Trading Volume: 960,885
Technical Sentiment Consensus Rating: Buy
Current Market Cap: $14.2B
Find detailed analytics on ICLR stock on TipRanks’ Stock Analysis page.